.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

NEVANAC Drug Profile

« Back to Dashboard
Nevanac is a drug marketed by Alcon Pharms Ltd and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug.

This drug has twenty-two patent family members in twenty-two countries.

The generic ingredient in NEVANAC is nepafenac. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the nepafenac profile page.

Summary for Tradename: NEVANAC

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Drug Prices: :see details

Pharmacology for Tradename: NEVANAC

Clinical Trials for: NEVANAC

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alcon Pharms Ltd
NEVANAC
nepafenac
SUSPENSION/DROPS;OPHTHALMIC021862-001Aug 19, 2005RXYes7,834,059Jan 31, 2027
Alcon Pharms Ltd
NEVANAC
nepafenac
SUSPENSION/DROPS;OPHTHALMIC021862-001Aug 19, 2005RXYes8,071,648Dec 2, 2025Y
Alcon Pharms Ltd
NEVANAC
nepafenac
SUSPENSION/DROPS;OPHTHALMIC021862-001Aug 19, 2005RXYes8,324,281Dec 2, 2025Y
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: NEVANAC

These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Alcon Pharms Ltd
NEVANAC
nepafenac
SUSPENSION/DROPS;OPHTHALMIC021862-001Aug 19, 20055,475,034<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: NEVANAC

Country Document Number Estimated Expiration
European Patent Office1819362<disabled in preview>
China101068573<disabled in preview>
South Korea20070089687<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: NEVANAC

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
301Luxembourg<disabled>PRODUCT NAME: NEPAFENAC-SUSPENSION OPHTALMIQUE
0716600/01Switzerland<disabled>PRODUCT NAME: NEPAFENAC; REGISTRATION NUMBER/DATE: SWISSMEDIC 58745 24.09.2008
2013 00055Denmark<disabled>PRODUCT NAME: NEPAFENAC (3 MG/ML), HERUNDER NEPAFENAC I KOMBINATION MED GLACTOMANNANPOLYMERER, ISAER 3 MG/ML NEPAFENAC I KOMBINATION MED GALACTOMANNANPOLYMERER, SAMT OFTALMISKE SAMMENSAETNINGER DERAF; REG. NO/DATE: EU1/07/433/002 20130503
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc